Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical proucts coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
What will you be talking about during your sessions at AMCP 2022?
AMCP is this spring is in Chicago. My company, IPD Analytics, and myself and my partner Leslie Fish are doing 2 different sessions. They're both pipeline sessions. The first pipeline session will be on traditional pharmaceuticals; that's on Thursday. And then on Friday morning, we're giving the pipeline session on specialty pharmaceuticals.
The traditional session will cover some unique twists on legal and FDA issues that sometimes inhibit launch of products for traditional pharmaceuticals. Then we'll go into the generic pipeline—how payers can save money on products becoming multisource in the coming months; the 505(b)(2) pipeline, that's when manufacturers bring products to market using other products—clinical studies will give some 505(b)(2) pipeline a heads up—and then the brand traditional pharmaceutical pipeline, including new novel products coming to market and also sNDA [supplemental new drug application] products, where they're getting new indications and those new indications could add significant spend. So, that's the traditional one.
On the specialty side, we're going to look at what happened in 2021, give the pipeline outlook for 2022, and then also dig in deep on a couple biosimilar products coming to market, most notably Humira [adalimumab]. And there's been some big changes for payers to understand in the last couple of weeks for both the old formulation and the new formulation.
What other presentations are you looking forward to checking out at AMCP 2022?
I go to AMCP for various reasons. I think, especially in the last couple years with COVID-19, you haven't seen your colleagues that you're used to seeing at different meetings, both pharma colleagues and payer colleagues and other folks you look forward to seeing. I like networking with them. We're in our boxes here working at home so we don't get to interact as much. So, I think I go to AMCP for 2 reasons. One to learn from my colleagues and peers, and then also I go to the session to learn.
The sessions that I'm thinking about are digital therapeutics. IPD is digging into that pretty deep, so I like to hear what other people are thinking. I'm not a big Medicaid guy, but there's 2 Medicaid sessions. One is on carve-in and carve-out for the state programs; I'm interested in that. And also, there's a 340B/Medicaid discussion. 340B is important for anybody in pharmaceuticals today. And then lastly, there's a session on value-based contracting. There's usually a session on that, but I don't think anybody's solved that puzzle and I'm always interested in the next piece of the puzzle.